Qiagen (NYSE:QGEN) Updates Q1 2025 Earnings Guidance

Qiagen (NYSE:QGEN) issued an update on its first quarter 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 0.500- for the period, compared to the consensus earnings per share estimate of 0.500. The company issued revenue guidance of $472.8 million-, compared to the consensus revenue estimate of $477.5 million. Qiagen also updated its FY 2025 guidance to 2.280- EPS.

Qiagen Price Performance

Shares of Qiagen stock traded up $0.40 on Wednesday, hitting $43.76. The company’s stock had a trading volume of 1,533,236 shares, compared to its average volume of 1,163,455. Qiagen has a 52-week low of $40.15 and a 52-week high of $49.30. The company has a market capitalization of $9.71 billion, a P/E ratio of 109.09, a price-to-earnings-growth ratio of 3.10 and a beta of 0.36. The firm has a fifty day moving average price of $43.80 and a 200-day moving average price of $43.26. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39.

Qiagen (NYSE:QGEN) last released its earnings results on Wednesday, February 5th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.60 by $0.01. Qiagen had a net margin of 4.73% and a return on equity of 13.43%. On average, equities research analysts expect that Qiagen will post 2.23 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on QGEN shares. Hsbc Global Res raised shares of Qiagen to a “hold” rating in a research report on Thursday, October 17th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a report on Monday, January 6th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $52.50 price objective (up previously from $40.83) on shares of Qiagen in a report on Tuesday, December 10th. Finally, HSBC lowered shares of Qiagen from a “buy” rating to a “hold” rating and set a $47.64 price objective on the stock. in a research note on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $50.07.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.